SCYNEXIS to Participate in Upcoming Investor Conferences
09/08/2021 - 08:30 AM
JERSEY CITY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Company will participate in the following virtual investor conferences in September.
Presentation details can be found below:
H.C. Wainwright 23 rd Annual Global Investment Conference Format: On demand presentation and 1-on-1 meetings Date and Time: Presentation available Monday, September 13 at 7 am ET, 1-on-1 meetings September 13-15Registration Link Cantor Fitzgerald Virtual Global Healthcare Conference Format: Live presentation and 1-on-1 meetings Date and Time: Thursday, September 30 from 2:40-3:10 pm ET (Track 2) The presentations and archived webcasts can be found on the SCYNEXIS website at: https://www.scynexis.com/news-media/events for 30 days following the event.
About SCYNEXIS SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME ® (ibrexafungerp tablets) , which was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. In addition, late-stage clinical investigation of ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (rVVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com .
CONTACT : Investor Relations Irina Koffler LifeSci Advisors Tel: (646) 970-4681ikoffler@lifesciadvisors.com
Media Relations Gloria Gasaatura LifeSci Communications Tel: (646) 970-4688ggasaatura@lifescicomms.com
SCYX Rankings
#3676 Ranked by Stock Gains
SCYX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Jersey City
About SCYX
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.